| BACKGROUND
Diabetes mellitus (DM) is an established risk factor for active tuberculosis (TB). 1 As globalization fuels rapid lifestyle changes throughout low-income and middle-income countries (LMIC), DM and TB are cooccurring in the same populations and in the same individuals. [2] [3] [4] [5] Globally, DM prevalence is increasing rapidly. Currently, 80% of global DM burden is in LMICs, 6 and DM is increasingly prevalent in lowincome populations. 7, 8 As the global DM burden shifts down the socioeconomic ladder, DM and TB comorbidity will increase, exacerbating each other in a bidirectional relationship. 2, 3 Diabetes mellitus weakens the immune system through impairing both innate and adaptive immune functions and leads to a greater risk of poor TB outcomes including worse clinical presentation, more symptoms, increased transmission, relapse, treatment failure, and death. [9] [10] [11] [12] [13] A seminal systematic review published in 2008 by Jeon and Murray found that DM causes a 3-fold lifetime increase in TB risk (relative risk = 3.11). 14 A more recent
List of Abbreviations: AIDS, acquired immune deficiency syndrome; DM, diabetes mellitus; FPG, fasting plasma glucose; HIV, human immunodeficiency virus; LMIC, low-income and middle-income countries; OGTT, oral glucose tolerance test; RPG, random plasma glucose; TB, tuberculosis; EPTB, extrapulmonary tuberculosis; GNIPC, gross national income per capita; HbA1c, glycated haemoglobin; PTB, pulmonary tuberculosis; MDR-TB, multidrug resistant tuberculosis; PPD, purified protein derivative systematic review published in 2017 found that DM doubles lifetime TB risk (RR = 2.0), 15 while another systematic review and meta analysis published in 2017 found a greater than 3-fold increase in TB risk (RR = 3.59). 1 Additionally, T2DM has been shown to be a risk factor for falling into poverty, which is another important risk factor for TB. 16 Regardless of the true degree of relative risk, DM is a known risk factor for TB and 15% of the global TB burden is now attributable to DM. 17 It is also possible that TB may exacerbate or even initiate DM through predisposing individuals to impaired glucose tolerance. 2, 10, 18, 19 Tuberculosis drugs (namely, rifampicin) make it more difficult to maintain glucose control. 10 Although many studies have quantified the severity of the TB-DM comorbidity and described cooccurrence, this information is not well synthesized in the literature. Thus, there is a paucity of concise, summarized information on current research findings regarding the TB-DM coprevalence. Understanding the levels and variations in coprevalence will provide essential guidance for further research, pol- 2 | METHODS
| Search strategy
We searched PubMed, Embase, Ovid Medline, and PsychINFO databases for peer reviewed journal articles assessing DM in people with TB or TB in people with DM published between January 1990 and December 2016. We used all combinations of the following MeSH terms (and equivalent terms in Embase, Ovid Medline, and PsychINFO): "Tuberculosis," "Pulmonary Tuberculosis," or "Mycobacterium Tuberculosis," and "Diabetes Mellitus, or "Diabetes Mellitus, Type 2." We conducted a country specific search for all LMICs by searching MeSH terms "Tuberculosis" and "Diabetes Mellitus" along with each 2015 World Bank-classified LMIC name as classification (N = 135). All types of study designs were included. We included studies with the following characteristics: written in English; conducted in a LMIC; and provided DM prevalence among people with TB, or TB prevalence among people with DM, or both.
Studies with the following characteristics were excluded:
• exclusively among type 1 diabetes-because unlike type 2 DM, type 1 diabetes does not share many socioeconomic, environmental, and behavioural risk factors with TB, a primary focus of this review; and
• studies from inpatient settings-because such studies were unlikely to provide accurate insight into community-based DM and TB coprevalence.
| Data extraction
After removal of duplicates, 3 authors (HSM, ALR, and LN) independently screened titles and abstracts as per selection criteria. Any disagreements between reviewers at this stage were noted and discussed. Following abstract screening, HSM and AR reviewed the full text of remaining studies and identified additional relevant studies via a hand search of the reference lists of full-text-reviewed studies.
Following the full text review, studies that had no information or insufficient information on DM prevalence in people with TB or of TB prevalence in people with DM or were conducted only among inpatients were excluded. If 2 or more publications were from same cohort, the one with most comprehensive data points was used. Studies that received a quality score ≤ 2 (described below) were excluded.
For fully reviewed studies, data were gathered for the following variables: country, study setting, sample size, study design, sampling method, response rate, % female of study participants, age in years of study participants, HIV status of study participants, reported DM prevalence and/or reported TB prevalence, and method of DM diagnosis and/or TB diagnosis.
| Quality assessment
We did a structured quality assessment scoring system for each study in the review. The scoring was adopted from previous review and allowed more accurate comparison across studies. Quality assessments were based on the following criteria: sampling methods used, TB diagnosis for studies reporting TB prevalence among people with DM, DM diagnosis for studies reporting DM prevalence among people with TB, response rate, and reporting specificity (Tables 1-4 ). All criteria were weighed equally, and each included study received a score of 0, 1, or 2 for each criterion (except for the specificity criterion, which received scores of 0 or 1). Therefore, possible quality scores ranged from 0 to 7. The studies were classified into 3 groups: high quality (6-7) medium quality (3) (4) (5) , and low quality (1-2). Due to the diversity of study populations, study methods, nonreporting of standard errors, and wide heterogeneity of results, we did not metaanalyse the data and instead present the results in a narrative form.
This review has followed the Cochrane Collaboration guidelines, and the results are reported according to the PRISMA checklist (Table 5) .
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| RESULTS
The initial search of Ovid Medline, PubMed, PsychInfo, and Embase resulted in 5141 articles ( Figure 1 Prospective cohort n/a n/a n/a n/a 13.4
Self report/RPG Prospective cohort n/a n/a n/a n/a 12.3
Self-report/RPG Prospective cohort n/a n/a n/a None exists Eligibility criteria 6 Specify study characteristics (eg, PICOS and length of follow-up) and report characteristics (eg, years considered, language, and publication status) used as criteria for eligibility, giving rationale.
4-5
Information sources 7 Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
4
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
4-5
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
5
Data items 11 List and define all variables for which data were sought (eg, PICOS and funding sources) and any assumptions and simplifications made. Study characteristics 18 For each study, present characteristics for which data were extracted (eg, study size, PICOS, and follow-up period) and provide the citations. consider their relevance to key groups (eg, healthcare providers, users, and policy makers).
9-10
Limitations 25 Discuss limitations at study and outcome level (eg, risk of bias) and at review-level (eg, incomplete retrieval of identified research and reporting bias).
(Continues)
The majority (n = 59) of studies measuring DM in TB patients uti- 
12-13
Funding Funding 27 Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review.
16
FIGURE 1 Flow chart of literature search Table 2 and Figure 2 show the included studies by countries, the World Bank Gross National Income Per Capita, and reported TB and DM prevalence in the general population. Most of the studies included in this review came from middle-income countries, with India (n = 17), China (n = 11), and Mexico (n = 7) providing more than a third of included studies. Table 3 shows great variance in DM prevalence among TB patients ranging from below 3% in some West African studies (Guinea, Guinea-Bissau, Benin, and Nigeria), to over 35% and even 40% in some studies from Mexico and India, to 45% in the Marshall Islands. In most studies, estimates of DM prevalence among people with TB were 10% to 20% (Table 2 ). Table 4 demonstrates that fewer studies provide TB prevalence among DM patients. Nevertheless, the studies in this report TB prevalence among patients with DM range from 0.1% in China to 4.9% in Ethiopia.
| Africa
Nineteen studies from Africa were included. Thirteen studies presented data on DM prevalence among TB patients, which ranged from less than 2% in urban-referral settings in Benin and Nigeria to over 15% in urban referral and nonreferral settings in Ethiopia and Tanzania. Six studies presented prevalence of TB among DM patients and reported prevalence ranged from 1% in an urban referral setting in South Africa to 4.9% in an urban referral setting in Ethiopia,
| Americas
Twelve studies from the Americas were included, which all analysed DM prevalence among TB populations. Mexico was best-represented country, accounting for 7 of the 12 studies. Diabetes mellitus-TB coprevalence ranged from 3.7% in a nation-wide registry study from Brazil to 36.1% in an urban referral-setting study from Mexico.
| Central Asia, Western Asia, Eastern Europe
Three studies from Central Asia, Western Asia, or Eastern Europe were included, all provided data on DM prevalence among TB populations. Reported DM-TB coprevalence ranged from 1.4% in a nationwide study in Kazakhstan to 18.7% in an urban referral setting from Kyrgyzstan.
| East Asia
Eleven studies from East Asia were included, all from China. Eight reported DM prevalence among TB populations with reported prevalence ranging from 6.3% in the rural community-based setting to 30.8% in an urban referral setting. Three studies reported TB prevalence among people living with DM and reported TB-DM coprevalence ranged from 0.1% in one mixed nonreferral study, to 0.49% in the other mixed nonreferral study.
| Middle East
Three studies from the Middle East were included with 2 studies from Turkey reporting DM prevalence among people with TB, one reporting 8.6% in an unspecified setting and the other reporting 16% from an urban referral setting. One study from Iran reported TB coprevalence among people with DM of 1%.
FIGURE 2 Prevalence of diabetes and tuberculosis in low-income and middle-income countries
| South East Asia
Eight studies from South East Asia were included; all reported DM-TB coprevalence among TB populations, which ranged from 12.5% in a nonreferral setting in Malaysia, to 41.3% in an urban referral setting also in Malaysia.
| South Asia
Twenty-five studies from South Asia were included. Twenty reported DM prevalence among TB populations, with results ranging from 7.3%
in a rural primary setting in India to 44% in an urban-rural mixed nonreferral setting in India. Five studies reported TB prevalence among people living with DM; reported prevalence ranged from 0.2% in Bangladesh to 4.1% in a country-wide referral study from Pakistan.
| Pacific
Five studies from the pacific were included in this review; 3 reported Both DM and TB prevalence in the included studies were higher than the estimated national prevalence. However, the prevalence of TB among patients with DM was several folds higher the than reported national prevalence. Higher risk of TB among diabetes patients alone cannot explain this. The possible explanations are that many of the reports were from tertiary care centres or among patients with TB symptoms who are at much higher risk than general population. Further, use of diagnostic tools with low specificity such as clinical criteria and chest X-ray may have resulted in many false positive diagnosis.
Although the focus of our review was different from that of Workneh et al, and despite a significant variation in the included studies, our report produced strikingly similar regional coprevalences, each lending credence to the other. 20 In addition to utilizing highly varied TB and DM screening methodology, most studies did not provide data on age, body mass index, socioeconomic status, tobacco usage, or nutrition status. This, in addition to the highly varied screening methodologies, made it impossible to adjust for these important factors when comparing co-prevalence rates and prevented from reasonable meta-analysis or subgroup meta-analysis. The active case finding of studies also added difficulty when compared with passive case finding reported in national surveillance. 101, 103 Lastly, these coprevalences likely do not fully reflect the bidirectional relationship between DM and TB due to the confounding effect of BMI. 15 Because high BMI protects against TB while also predisposing to DM, the protective effect of higher BMIs in DM patients likely masks the strength of DM as a risk factor TB. 15 Nevertheless, the current research on DM-TB co-occurrence highlights the pressing need for timely intervention, as epidemics of self-exacerbating, co-morbid conditions, such as DM and TB, must be addressed early and aggressively. 4, 124 Lessons from the human immunodeficiency virus (HIV)-TB epidemic highlight this fact. 4 While HIV is by far the strongest individual risk factor for TB, at the population level, the effect of diabetes on TB is higher. 125 For example, it is estimated that HIV accounted for 3.4% of India's TB burden in 2000, while diabetes accounted for 14.8% of the burden that year. 126 Globally, there are now more TB patients with concomitant DM than TB patients with concomitant HIV infection. 127 If the rise of global diabetes prevalence was halted at 2015 levels, by 2035, 6 million new TB infections and 1.5 million deaths would be prevented, a number equal to the number of deaths from TB in 2014. 128 As diabetes prevalence escalates, it is critical to address the large and growing coepidemic between DM and TB.
Important trends in the DM-TB comorbidity emerged from this review. First, wide regional and income-level variations exist in terms of where comorbidity research is taking place; the majority of research is conducted in middle-income countries, most prominently in India, China, Brazil, and Mexico. This reflects the centrality of middle-income countries to the TB-DM comorbidity epidemic as rapid urbanization, mechanization, and globalization have spurred escalations of diabetes incidence in these countries, while also often exacerbating persistent problems of overcrowding, income inequality, and even malnutrition that in turn fuel TB incidence. This review also demonstrated that many TB-DM studies in
LMICs take place in urban, tertiary care centres. As such, many low-income populations in these countries, such as rural dwellers and those who do not receive care in large referral settings, were largely absent from this analysis, which reflects the fact that most global DM research includes only higher-income urban populations. On the one hand, such a focus is merited, given the lifestyles associated with urban living, yet this focus is also limiting as it fails to take seriously the increasing incidence of DM among urban and rural lower-income populations in LMICs. This omission is significant because as diabetes moves down the socioeconomic gradient throughout LMICs, the disease will increasingly burden these most vulnerable populations and TB-DM comorbidity will continue to rise.
Finally, only studies from India and China assessed scalable screening projects or procedures. 58, 59, 72, 100, 101, 103 As of now, India is the only country in which DM screening has been built into the national TB control program. The paucity of studies examining or proposing bidirectional screening procedures speaks to the urgent need for the development of comprehensive, scalable bidirectional screening programs that will reach beyond urban referral centres and serve rural, low-income populations in LMICs who are most at risk for TB-DM comorbidity. 129 Such screening programs are expected to result in earlier DM identification in TB patients and opportunities for better control and management of comorbidity.
The World Health Organization in its collaborative framework for care and control of TB and diabetes 130 has suggested that DM screening and care be integrated into existing TB care systems, in which most LMICs have successful registration, recording, and reporting mechanisms that allow for close patient follow-up and careful collection of outcome data. 129, 131, 132 Yet, pilot studies highlight the following crucial issues facing screening programs: loss of follow up care, iatrogenic hyperglycaemia in TB patients, low casedetection rate for both diseases, lack of human resources, and lack of monitoring and evaluation capabilities. 131, 133 In addressing these challenges to bring coordinated care beyond large referral centres in LMICs, big data sources such as the Global Burden of Disease Study, which currently largely overlook comorbidity issues, may prove extremely useful.
Future research on DM-TB comorbidity should focus on developing scalable, standardized screening and treatment programs including optimal treatment protocols for treating TB in people with DM. 134 Future studies should be nationally representative and should focus on remedying the challenges identified by previous studies and adapting lessons learned from the HIV/AIDS epidemic. Also, as previously discussed, it will be crucial for future research to include socioeconomic variables, as transforming, globalizing socioeconomic landscapes will lie at the centre of this coepidemic.
| CONCLUSION
This review provides a summary of the existing literature on the coprevalence of TB and DM in LMICs. In all regions, included studies reported coprevalence to be substantially higher than prevalence of either of these two diseases in general populations. This review provides further impetus to the previous calls for increased research into comorbidity screening programs, which would achieve diagonal care
by integrating DM screening into existing TB care frameworks, or in some cases, TB screening into DM care settings. There is an urgent need for standardized and scalable integrated comorbidity screening programs in LMICs, without which the progress achieved against TB cannot be sustained. 
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